Drug Interactions between fenfluramine and vadadustat
This report displays the potential drug interactions for the following 2 drugs:
- fenfluramine
- vadadustat
Interactions between your drugs
fenfluramine vadadustat
Applies to: fenfluramine and vadadustat
MONITOR: Coadministration with vadadustat may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of the CYP450 2B6 isoenzyme. Vadadustat is an inducer CYP450 2B6 in vitro. However, clinical data are not available.
MANAGEMENT: Some authorities recommend using caution when vadadustat is used concomitantly with drugs that are substrates of CYP450 2B6, particularly sensitive substrates or those with a narrow therapeutic range. Monitoring for potential loss of therapeutic efficacy is recommended. The prescribing information for concomitant medications may be consulted to assess the benefits versus risks of coadministration, as well as any dosage adjustments that may be required during coadministration and/or following the discontinuation of a CYP450 2B6 inducer.
References (3)
- (2023) "Product Information. Vafseo (vadadustat)." Adjutor Healthcare Pty Ltd
- (2024) "Product Information. Vafseo (vadadustat)." Akebia Therapeutics
- (2024) "Product Information. Vafseo (vadadustat)." Medice UK Ltd
Drug and food interactions
fenfluramine food
Applies to: fenfluramine
GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.
MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (3)
- Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
- (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
- (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals
vadadustat food
Applies to: vadadustat
MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.
MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.
References (3)
- (2023) "Product Information. Vafseo (vadadustat)." Adjutor Healthcare Pty Ltd
- (2024) "Product Information. Vafseo (vadadustat)." Akebia Therapeutics
- (2024) "Product Information. Vafseo (vadadustat)." Medice UK Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.